论文部分内容阅读
采用免疫组化染色技术，检测７５例原发乳腺癌组织中雌激素受体（ＥＲ），表皮生长因子受体（ＥＧＦＲ）及ｐ５３的表达。结果表明：ＥＲ、ＥＧＦＲ、ｐ５３的阳性表达率分别为４９．３％、４１．３％和３７．３％。ＥＲ、ＥＧＦＲ的表达与腋淋巴结转移、临床分期有明显相关性（Ｐ＜０．０５）；与年龄及肿瘤大小无明显相关性（Ｐ＞０．０５）。ＥＧＦＲ与ＥＲ有负相关性（Ｐ＜０．０５）。在有４个以上腋淋巴结转移的２１例病例中，ＥＧＦＲ阳性者１４例，占６６．７％。２０例临床Ⅲ期的病例，ＥＧＦＲ阳性者１５例，占７５．０％。ｐ５３的表达与腋淋巴结转移、临床分期、年龄及肿瘤大小均无明显相关性（Ｐ＞０．０５）；与ＥＲ呈负相关性（Ｐ＜０．０５）；与ＥＧＦＲ呈正相关性（Ｐ＜０．０５）。研究认为ＥＧＦＲ蛋白表达阳性的乳腺癌病人预后不良，ｐ５３蛋白表达阳性与乳腺癌病人的预后无明显相关性。
Immunohistochemical staining was used to detect the expression of estrogen receptor (ER), epidermal growth factor receptor (EGFR) and p53 in 75 cases of primary breast cancer. The results showed that the positive expression rates of ER, EGFR, and p53 were 49.3%, 41.3%, and 37.3%, respectively. The expression of ER and EGFR was significantly correlated with axillary lymph node metastasis and clinical stage (P<0.05), and was not significantly related to age and tumor size (P>0.05). There was a negative correlation between EGFR and ER (P<0.05). Of the 21 cases with more than 4 axillary lymph node metastases, 14 were EGFR-positive, accounting for 66.7%. 20 cases of clinical stage III, 15 cases of EGFR positive, accounting for 75.0%. There was no significant correlation between p53 expression and axillary lymph node metastasis, clinical stage, age and tumor size (P>0.05). There was a negative correlation between p53 expression and ER (P<0.05) and a positive correlation with EGFR (P< 0.05). It is considered that the prognosis of breast cancer patients with positive EGFR protein expression is poor, and the positive expression of p53 protein has no significant correlation with the prognosis of breast cancer patients.